Geron Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Geron Corporation (GERN)
Track today's live Geron (GERN) share price, performance and key data on this page with our current NASDAQ:GERN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Geron share price on the NASDAQ exchange. Use the dropdown to switch exchange for the GERN share price, head to our technical summary section, which provides analysis on Geron share price buy/sell indicators using real-time data (or discuss the Geron (GERN) stock price today with other investors in the Geron NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:GERN share price (ISIN: US3741631036) to enhance your trading decisions with our free investment tools and resources.
What Is the Geron Corporation Share Price Today?
The Geron share price today is 0.9898.
What Is the Stock Symbol for Geron Corporation
The stock symbol (or 'ticker') for Geron Corporation is "GERN."
What Stock Exchange Does Geron Corporation Trade On?
Geron Corporation is listed and trades on the NASDAQ stock exchange.
Is Geron Corporation a Good Stock to Buy?
Determining whether Geron (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:GERN share price (ISIN: US3741631036) to enhance your trading decisions with our free investment tools and resources.
What Is the Geron Corporation Share Price Today?
The Geron share price today is 0.9898.
What Is the Stock Symbol for Geron Corporation
The stock symbol (or 'ticker') for Geron Corporation is "GERN."
What Stock Exchange Does Geron Corporation Trade On?
Geron Corporation is listed and trades on the NASDAQ stock exchange.
Is Geron Corporation a Good Stock to Buy?
Determining whether Geron (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9500
1.0200
52 wk Range
0.8400
2.0100
GERN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.95001.0200
52 wk Range
0.84002.0100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GERN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
3.6250
Upside
+266.24%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Why is Geron stock sliding today?- Investing.com
Form 8K Geron Corporation For: 4 November- Investing.com
- Geron Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Geron Corporation For: 4 November
- Investing.com
Form 8K Geron Corporation For: 28 October- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.6250
(+266.24% Upside)
Geron Corporation SWOT Analysis
Rytelo's Rise | Explore Geron's flagship product Rytelo, driving sales growth and exceeding market expectations, positioning the company as a rising star in hematologic malignancies |
Leadership Shift | New CEO appointment signals potential strategic changes, aiming to capitalize on Rytelo's success and diversify Geron's product pipeline |
Market Expansion | Delve into Geron's growth prospects, including European Union approval for Rytelo and potential new indications, with analysts projecting significant revenue growth |
Analyst Outlook | Average price target of $4.00, with "Overweight" ratings reflecting optimism despite challenges. EPS projections show improvement trend from -0.09 to -0.00 |
Geron Corporation Earnings Call Summary for Q3/2026
- Q3 2026 revenue rose 27% YoY to $60.1M, missing consensus by $0.5M; shares gained 4.29% premarket on sustained demand growth trajectory.
- Company reaffirmed FY 2026 revenue guidance of $220M-$240M, targeting mid-to-high end; cut operating expense outlook by $10M to $220M-$230M.
- RYTELO posted fourth consecutive quarter of demand growth, up 10% sequentially; prescriber base expanded 8% to over 1,700 accounts since launch.
- Cash position strengthened to $339M from $327M prior quarter; gross-to-net deductions improved to 19.3% from 21.6% year-ago, aiding profitability.
- Germany launch expected by end-2026, France in 2027; management pursuing BD opportunities in hematology/oncology aligned with community care model.
Last Updated: 04/11/2026, 13:46
Read Full TranscriptEarnings
Latest Release
04/11/2026
EPS / Forecast
-- / -0.01
Revenue / Forecast
60.19M / 60.69M
Compare GERN to Peers and Sector
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.3x | −3.0x | −0.2x | |
PEG Ratio | −0.36 | 0.01 | 0.00 | |
Price/Book | 2.8x | 1.9x | 2.6x | |
Price / LTM Sales | 2.9x | 5.8x | 2.8x | |
Upside (Analyst Target) | 266.2% | 111.9% | 65.6% | |
Fair Value Upside | Unlock | −13.9% | 10.0% | Unlock |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Geron (NASDAQ: GERN) Share Price Today?
The Geron stock price today is 0.9898 USD.
What Stock Exchange Does Geron (GERN) Trade On?
Geron is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Geron?
The stock symbol (also called a 'ticker') for Geron is "GERN."
What Is the Current Geron Market Capitalisation?
As of today, Geron (NASDAQ: GERN) market cap is 612.0900M USD.
What Is Geron's (GERN) Earnings Per Share (TTM)?
The Geron EPS is currently -0.071 (Trailing Twelve Months).
When Is the Next Geron Earnings Date?
Geron's next earnings report will be released on 03/03/2027.
Is GERN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Geron moving averages and other technical indicators, the daily buy/sell signal for GERN stock is Strong Sell.
How Many Times Has Geron Stock Split?
Geron has split 0 times. (See the GERN stock split history page for full effective split date and price information.)
How Many Employees Does Geron Have?
Geron has 258 employees, based on their latest Companies House report.
What is the current trading status of Geron (NASDAQ: GERN)?
As of 07/11/2026, Geron (GERN) is trading at a share price of 0.9898 USD, with a previous close of 0.9898 USD. The stock has fluctuated within a day range of 0.9500 USD to 1.0200 USD, while its 52-week range spans from 0.8400 USD to 2.0100 USD.
What Is Geron (GERN) Price Target According to Analysts?
The average 12-month price target for Geron is 3.6250 USD, with a high estimate of 5 USD and a low estimate of 2.5 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +266.24% Upside potential.
What Is the GERN Premarket Price?
GERN's last pre-market stock price is 0.9500 USD. The pre-market share volume is 45,080.0000, and the stock has decreased by -0.0001, or -0.0100%.
What Is the GERN After Hours Price?
GERN's last after hours stock price is 1.0000 USD, the stock has decreased by 0.0102, or 1.0300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.